Serial No.: 10/587,085 Office Action Mailed April 21, 2009 Page 5 of 8

REMARKS

Favorable reconsideration is requested in view of the above amendments and following remarks. Claims 1-6 and 14-17 have been amended. The amendment to claims 5 and 15 are supported by the original disclosure, for example, at page 17, lines 2-6 of the specification. Claims 1-4, 6, 14 and 16-17 have been amended editorially. No new matter has been added. Claims 1-17 remain pending in the application.

Claim Objections

Claim 14 is objected to for informalities. Claim 14 has been amended, taking the issues noted in the objection into account.

Withdrawal of the objection is respectfully requested.

Claim Rejections - 35 USC § 101

Claims 1-5 are rejected under 35 USC 101 because the claimed invention is directed to non-statutory subject matter. Claims 1-3 recite an isolated polypeptide. Claims 4-5 recite an isolated DNA. Claims 1-5 are directed to statutory subject matter.

Withdrawal of the rejection is respectfully requested.

Claim Rejections - 35 USC § 112

Claims 1-17 are rejected under 35 USC 112, second paragraph, as being indefinite.

Claim 1 recites an isolated polypeptide consisting of the amino acid sequence identified in (a) or (b). Claim 1(a) recites the amino sequence of SEQ ID NO: 1. Claim 5 recites an isolated DNA consisting of the nucleotide sequence identified in (a), (b) and (c). Claim 5(a) and (c) recite the nucleotide sequence of SEQ ID NO: 3. Claim 5(b) and claim 15(b) recite a nucleotide sequence that is capable of hybridizing, under stringent conditions, to a DNA having a nucleotide sequence that is complementary to the nucleotide sequence of SEQ ID NO: 3, the stringent conditions being washing with an aqueous solution consisting of 1.5 mM trisodium citrate, 15 mM sodium chloride and 0.1% sodium dodecyl sulfate at 65°C. Claims 15 and 16 depend from claim 14. Accordingly, Applicants respectfully submit that claims 1-17 are definite.

Enablement

Claims 1-17 are rejected under 35 USC 112, first paragraph, as failing to comply with the enablement requirement. As indicated above, claim 1 recites an isolated polypeptide consisting of the amino acid sequence identified in (a) or (b). Claim 1(a) recites the amino acid sequence of

Serial No.: 10/587,085 Office Action Mailed April 21, 2009 Page 6 of 8

derived from SEQ ID NO: 3.

SEQ ID NO: 1. Claim 1(b) recites an amino acid sequence resulting from substitution, insertion, deletion, and/or addition of one amino acid in the amino acid sequence of SEQ ID NO: 1. Claim 1 further recites that the isolated polypeptide has amidase activity. Thus, claim 1 is limited to those polypeptides having amidase activities that are derived from SEQ ID NO: 1. Claim 5 recites an isolated DNA consisting of the nucleotide sequence identified in (a), (b) and (c). Claim 5 recites that the isolated DNA encodes a polypeptide having amidase activity. Claim 15 recites the use of a recombinant plasmid including a DNA consisting of the nucleotide sequence identified in (a), (b) and (c). Claim 15 also recites that the DNA included in the recombinant plasmid encodes a polypeptide having amidase activity. Thus, claims 5 and 15 likewise are limited to those polynucleotides encoding for polypeptides having amidase activities that are

Accordingly, Applicants respectfully submit that claims 1-17 are commensurate in scope of the specification.

Deposit

Claims 3, 8, 11, 13 and 15 are rejected because the bacterial strains are not publicly available. To satisfy the deposit requirement for deposits made under the Budapest Treaty, the Examiner required a statement that the specific strains have been deposited under the Budapest Treaty and that the strain will be available to the public under the conditions specified in 37 CFR 1.808. A Communication Regarding Deposit is submitted herewith. Applicants submit that the Communication satisfies the deposit requirements under 37 CFR §§ 1.803-1.808.

Based on the forgoing, Applicants respectfully request withdrawal of the enablement rejection.

Written Description

Claims 1-17 are rejected under 35 USC 112, first paragraph, as failing to comply with the written description requirement. Regarding claims 1-3 and 12-16, claim 1 is limited to those polypeptides having amidase activities that are derived from SEQ ID NO: 1. Regarding claims 4-11, 15 and 17, claims 5 and 15 are limited to those polynucleotides encoding for polypeptides having amidase activities that are derived from SEQ ID NO: 3. The polypeptides of claim 1 are described on page 15, lines 1-7 of the specification. The polynucleotides of claims 5 and 15 are described on page 17, lines 7-17 of the specification. Accordingly, Applicants respectfully submit that claims 1-17 comply with the written description requirement.

Serial No.: 10/587,085 Office Action Mailed April 21, 2009 Page 7 of 8

Claim Rejections - 35 USC § 102

Page 8/13

Claims 1, 4-7, 9, 10, 14, 15 and 17 are rejected under 35 USC 102(e) as being anticipated by US Publication No. 2004/0023257 (Barton et al.). Applicants respectfully traverse the rejection.

Barton et al. disclose amino acid sequences of polypeptides having amidase activity. The reference further discloses nucleotide sequences of polynucleotides encoding polypeptides that have amidase activity.

However, Barton et al. do not disclose an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence resulting from substitution, insertion, deletion, and/or addition of one amino acid in the amino acid sequence of SEQ ID NO: 1 as recited in claim 1.

Barton et al. further do not disclose the isolated DNA consisting of the nucleotide sequence of SEQ ID NO: 3, a nucleotide sequence that is capable of hybridizing under stringent conditions to a DNA having the nucleotide sequence that is complementary to the nucleotide sequence of SEQ ID NO: 3, the stringent conditions being washing with an aqueous solution consisting of 1.5 mM trisodium citrate, 15 mM sodium chloride and 0.1% sodium dodecyl sulfate at 65°C, or a nucleotide sequence resulting from substitution, insertion, deletion, and/or addition of one nucleotide in the nucleotide sequence of SEQ ID NO: 3.

Accordingly, Barton et al. do not anticipate claims 1 and 5 and their dependent claims.

Claims 1, 2, 4-7, 9, 10, 12 and 14-17 are rejected under 35 USC 102(b) as being anticipated by Archives of Biochemistry and Biophysics, Vol. 338, No. 1, pp. 22-28 (Takegawa et al.). Applicants respectfully traverse the rejection.

Takegawa et al. disclose the nucleotide sequence of the gene encoding endo- β -N-acetylglucosaminidase from *Arthrobacter protophormiae*.

However, Takegawa et al. do not disclose an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence resulting from substitution, insertion, deletion, and/or addition of one amino acid in the amino acid sequence of SEQ ID NO: 1 as recited in claim 1.

Takegawa et al. further do not disclose the isolated DNA consisting of the nucleotide sequence of SEQ ID NO: 3, a nucleotide sequence that is capable of hybridizing under stringent conditions to a DNA having the nucleotide sequence that is complementary to the nucleotide

Serial No.: 10/587,085

Office Action Mailed April 21, 2009

Page 8 of 8

sequence of SEQ ID NO: 3, the stringent conditions being washing with an aqueous solution consisting of 1.5 mM trisodium citrate, 15 mM sodium chloride and 0.1% sodium dodecyl sulfate at 65°C, or a nucleotide sequence resulting from substitution, insertion, deletion, and/or addition of one nucleotide in the nucleotide sequence of SEQ ID NO: 3.

Accordingly, Takegawa et al. do not anticipate claims 1 and 5 and their dependent claims.

Favorable reconsideration in the form of a notice of allowance is respectfully requested. Any questions regarding this communication can be directed to the undersigned attorney, Douglas P. Mueller, Reg. No. 30,300, at (612) 455-3804.

52835 PATENT TRADEMARK OFFICE Respectfully submitted,

HAMRE, SCHUMANN, MUELLER & LARSON, P.C. P.O. Box 2902-0902

Minneapolis, MN 55402-0902

Reg. No. 30,300

(612) 455,3800

DPM/ym

CENTRAL FAX CENTER JUL 2 1 2009

S/N 10/587,085

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Yanagisawa et al.

Examiner:

Sheridan Swope

Serial No.:

10/587,085

Group Art Unit:

1652

Filed:

July 21, 2006

Docket No .:

20162.0021USWO

Title:

POLYPEPTIDE HAVING AMIDASE ACTIVITY AND GENE THEREOF

CERTIFICATE UNDER 37 CFR 1.6(d):

21,2009

I hereby certify that this paper is being transmitted by facsimile to the U.

By: Name:

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

COMMUNICATION REGARDING DEPOSIT

Dear Sir:

The following microorganisms have been deposited with the National Institute of Advanced Industrial Science and Technology, AIST Tsukuba Central 6, 101, Higashi 1-chome, Tsukuba-shi, Ibaraki 305-8566, JAPAN, an international depository authority recognized by the Budapest Treaty.

Arthrobacter sp. KNK 1101J

International depository authority: National Institute of Advanced Industrial Science and Technology

Date of deposition: October 22, 2003 Accession Number: FERM BP-10192

Page 11/13

612.455.3801 HSML (JLS)

Serial No.: 10/587,085

Office Action Mailed April 21, 2009

Page 2 of 2

Escherichia coli HB101 (pHA002)

Intérnational Depository Authority: National Institute of Advanced Industrial Science and

Technology

Date of deposition: January 22, 2004 Accession Number: FERM BP-10193

The applicants affirm that all restrictions imposed by the depositor on the availability to the public of the deposited biological material will be irrevocably removed upon the granting of the patent except as permitted under 37 CFR 1.808(b).

52835 PATENT TRADEMARK OFFICE

Dated Whill Loog

DPM/ym

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER & LARSON, P.C. P.O. Box 2902-0902 Minneapolis, MN 55402-0902 (612) 455-3800

Iouglas P. Mueller Reg. No. 30,300

書式8(第7条第1项関係)

「特許手続上の微生物の脊託等の國際的承認 に関するブタベスト条約」

下記国際者託当局によって規則7.1に従い 発行する。 BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE
RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the INTERNATIONAL

DEPOSITARY AUTHORITY identified at the bottom of this page.

原寄託についての受託証

氏名 (名称)

寄託者

株式会社カネカ

代表取締役 武田 正利 殿

あて名 〒 530-8288

大阪市北区中之島3-2-4

大阪市北区中之高3~	2-4
I. 微生物の表示	
. 跖者が付した戦別のための表示)	(受託番号)
Arthrobactor sp.KNK1101]	FERM BP-10192
11. 科学的性質及び分類学上の位置	
[欄の微生物には、次の事項を記載した文章が能付きれ	ていた。
区 科学的性質	
② 分類学上の位置	
III. 原寄託申請の受託	
本園原告託当局は、 年 月 日に受領した!欄の	被生物を受託する。
IV. 移管申請の受託	
本国際各託当局は、平成 15 年 10 月 22 日(国内	受託日) に受託した (欄の微生物を受託する。
(平成 15 年 10 月 22 日に寄託されたFBRM P-1	9564 より移管)
V. 国家各託当局	
独立行政法人废案技術総合研究所 特許生裝	客託センター
名称 International Patent Organism Depositar National Institute of Advanced Industrial	
センタ	ター会 山岡 世報記刊出版記刊
Dr.Masa	kasu Yamaoka, Director 了一家皇

あて名 日本図 茨城県つくば市東1丁目1番地1 中央第6 (廊便番号305-8508)

AIST Tsukuba Central 6, 1-1, Higashi 1-chome Tsukuba-shi, ibaraki-ken 305-8566 Japan

平成 18 年 (04) 12 月 24 日

套式8(第7条第1項關係)

「特許平統上の微生物の寄託等の顧問的承認 に関するプタペスト条約」 BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

下記國際客託当局によって規則7.1に従い 発行する。 RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page.

原客託についての受託証

氏名 (名称)

寄託者

株式会社カネカ

代發取締役 武田 正利 殷

あて名

〒 530-8288

大阪市北区中之岛3-2-4

1. 微生物の表示	1.50.45 50.4
, 託者が付した機別のための表示)	(受託番号)
E. coll HB101 (pHA002)	PERM BP-10193
!!. 科学的性質及び分類学上の位置	
棚の微生物には、次の事項を記載した文章が続	付されていた。
区 科学的性質	
ビ 分類学上の位置	
lli. 原客託申請の受託	
本国際各託当局は、 年 月 日に受領した	1欄の微生物を受託する。
IV. 移管申請の受託	
本国際寄託当局は、平成 16 年 1 月 22 日(日	的内受託日)に受託したI欄の微生物を受託する。
(平成 16 年 1 月 82 日に寄託されたFBRM)	P- 19646 より移営)
V. 國際寄託当局	

Dr. Masakazu Yamaoka, Directo

あて名 日本国 茨城県つくば市東1丁目1番地1 中央第6(鄭便番号305-8566)

AIST Taukuba Central 6, 1-1, Higashi 1-chome Tsukuba-shi. Ibaraki-ken 305-8566 Japan

平成 16 年 (04) 12 月 24 日